The Hypothalamic-Pituitary-Adrenal Axis in Borderline Personality Disorder: A Review

REFERENCES

• McGlashan T H, Grilo C M, Sanislow C A, et al. Two-year prevalence and stability of individual criteria for schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders. Am J Psychiatry 2005; 162: 833–89
   Google Scholar
• Zanarini M C, Frankenburg F R, Reich D B, Silk K R, Hudson J I, McSweeney L B. The subsyndromal phenomenology of borderline personality disorder: a 10-year follow-up study. Am J Psychiatry 2007; 164: 929–35
   PubMed Web of Science ®Google Scholar
• Zanarini M C, Gunderson J G, Frankenburg F R, Chauncey D L. Discriminating borderline personality disorder from other Axis II disorders. Am J Psychiatry 1990; 147: 161–7
   PubMed Web of Science ®Google Scholar
• Ellison J M, Blum N R, Barsky A J. Frequent repeaters in a psychiatric emergency service. Hosp Community Psychiatry 1989; 40: 958–60
   PubMedGoogle Scholar
• Linehan M M, Heard H L, Armstrong H E. Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients. Arch Gen Psychiatry 1993; 50: 971–4
   PubMed Web of Science ®Google Scholar
• Bateman A, Fonagy P. Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. Am J Psychiatry 1999; 156: 1563–9
   PubMed Web of Science ®Google Scholar
• Bateman A, Fonagy P. Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. Am J Psychiatry 2001; 158: 36–42
   PubMed Web of Science ®Google Scholar
• Blum N, Pfohl B, John D S, Monahan P, Black D W. STEPPS: a cognitive-behavioral systems-based group treatment for outpatients with borderline personality disorder—a preliminary report. Compr Psychiatry 2002; 43: 301–10
   PubMed Web of Science ®Google Scholar
• Clarkin J F, Levy K N, Lenzenweger M F, Kernberg O F. Evaluating three treatments for borderline personality disorder: a multiwave study. Am J Psychiatry 2007; 164: 922–8
   PubMed Web of Science ®Google Scholar
• Skodol A E, Gunderson J G, Pfohl B, Widiger T A, Livesley W J, Siever L J. The borderline diagnosis I: psychopathology, comorbidity, and personality structure. Biol Psychiatry 2002; 51: 936–50
   PubMed Web of Science ®Google Scholar
• Yen S, Pagano M E, Shea M T, et al. Recent life events preceding suicide attempts in a personality disorder sample: findings from the Collaborative Longitudinal Personality Disorders Study. J Consult Clin Psychol 2005; 73: 99–105
   PubMed Web of Science ®Google Scholar
• Brain K L, Haines J, Williams C L. The psychophysiology of self-mutilation: evidence of tension reduction. Arch Suicide Res 1998; 4: 227–42
   Web of Science ®Google Scholar
• Stanley B, Brodsky B. Suicidal and self-injurious behavior in borderline personality disorder: the self-regulation action model. Understanding and treating borderline personality disorder, J Gunderson, P Hoffman. American Psychiatric Press, Washington, DC 2005
   Google Scholar
• Sachsse U, Von der Heyde S, Huether G. Stress regulation and self-mutilation. Am J Psychiatry 2002; 159: 672
   PubMedGoogle Scholar
• Stiglmayr C E, Ebner-Priemer U W, Bretz J, et al. Dissociative symptoms are positively related to stress in borderline personality disorder. Acta Psychiatr Scand 2008; 117: 139–47
   PubMed Web of Science ®Google Scholar
• Pagano M E, Skodol A E, Stout R L, et al. Stressful life events as predictors of functioning: findings from the Collaborative Longitudinal Personality Disorders Study. Acta Psychiatr Scand 2004; 110: 421–9
   PubMed Web of Science ®Google Scholar
• Jovev M, Jackson H J. The relationship of borderline personality disorder, life events and functioning in an Australian psychiatric sample. J Pers Disord 2006; 20: 205–17
   PubMed Web of Science ®Google Scholar
• Linehan M M, Heard H L, Armstrong H E. Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients. Arch Gen Psychiatry 1993; 50: 971–4
   PubMed Web of Science ®Google Scholar
• Carroll B J, Martin F I, Davies B. Pituitary-adrenal function in depression. Lancet 1968; 1: 1373–4
   Google Scholar
• Carroll B J, Feinberg M, Greden J F, et al. A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Arch Gen Psychiatry 1981; 38: 15–22
   PubMed Web of Science ®Google Scholar
• Arana G W, Baldessarini J R, Ornsteen M. The dexamethasone suppression test for diagnosis and prognosis in psychiatry. Arch Gen Psychiatry 1985; 42: 1193–204
   PubMed Web of Science ®Google Scholar
• Ribeiro S C, Tandon R, Grunhaus L, Greden J F. The DST as a predictor of outcome in depression: a meta-analysis. Am J Psychiatry 1993; 150: 1618–29
   PubMed Web of Science ®Google Scholar
• Yehuda R, Southwick S M, Nussbaum G, Wahby V, Giller E L, Jr., Mason J W. Low urinary cortisol excretion in patients with posttraumatic stress disorder. J Nerv Ment Dis 1990; 178: 366–9
   PubMed Web of Science ®Google Scholar
• Yehuda R. Advances in understanding neuroendocrine alteration in PTSD and their therapeutic implications. Ann N Y Acad Sci 2006; 1071: 137–66
   PubMed Web of Science ®Google Scholar
• Nemeroff C B. Neurobiological consequences of childhood trauma. J Clin Psychiatry 2004; 65(suppl 1)18–28
   PubMed Web of Science ®Google Scholar
• Claes S J. Corticotropin-releasing hormone (CRH) in psychiatry: from stress to psychopathology. Ann Med 2004; 36: 50–61
   PubMed Web of Science ®Google Scholar
• Pfennig A, Kunzel H E, Kern N, et al. Hypothalamus-pituitary-adrenal system regulation and suicidal behavior in depression. Biol Psychiatry 2005; 57: 336–42
   PubMed Web of Science ®Google Scholar
• Jokinen J, Carlborg A, Mårtensson B, Forslund K, Nordström A L, Nordström P. DST non-suppression predicts suicide after attempted suicide. Psychiatry Res 2007; 150: 297–303
   PubMed Web of Science ®Google Scholar
• Kendler K S, Karkowski L M, Prescott C A. Causal relationship between stressful life events and the onset of major depression. Am J Psychiatry 1999; 156: 837–41
   PubMed Web of Science ®Google Scholar
• Caspi A, Sudgen K, Moffitt T E, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301: 386–9
   PubMed Web of Science ®Google Scholar
• Sanchez M M, Ladd C O, Plotsky P M. Early adverse experience as a developmental risk factor for later psychopathology: evidence from rodent and primate models. Dev Psychopathol 2001; 13: 419–49
   PubMed Web of Science ®Google Scholar
• McEwen B S. Influences of the adrenocortical hormones on pituitary and brain function. Monogr Endocrinol 1979; 12: 467–92
   Google Scholar
• De Kloet C S, Vermetten E, Geuze E, Kavelaars A, Heinknen C J, Westenberg H GM. Assessment of HPA-axis function in posttraumatic stress disorder: pharmacological and non-pharmacological challenge tests, a review. J Psychiatr Res 2006; 40: 550–67
   PubMed Web of Science ®Google Scholar
• Clinton S, Miller S, Watson S J, Akil H. Prenatal stress does not alter innate novelty-seeking behavioral traits, but differentially affects individual differences in neuroendocrine stress responsivity. Psychoneuroendocrinology 2008; 33: 162–77
   PubMed Web of Science ®Google Scholar
• Macri S, Spinelli S, Adriani W, Dee Higley J, Laviola G. Early adversity and alcohol availability persistently modify serotonin and hypothalamic-pituitary-adrenal-axis metabolism and related behavior: what experimental research on rodents and primates can tell us. Neurosci Biobehav Rev 2007; 31: 172–80
   PubMedGoogle Scholar
• McCormick C M, Smith C, Mathews I Z. Effects of chronic social stress in adolescence on anxiety and neuroendocrine response to mild stress in male and female rats. Behav Brain Res 2008; 187: 228–38
   PubMed Web of Science ®Google Scholar
• Perez-Laso C, Segovia S, Martin J L, Ortega E, Gomez F, Del Cerro M C. Environmental prenatal stress alters sexual dimorphism of maternal behavior in rats. Behav Brain Res 2008; 187: 284–8
   Google Scholar
• Heim C, Nemeroff C B. Neurobiology of early life stress: clinical studies. Semin Clin Neuropsychiatry 2002; 7: 147–59
   PubMedGoogle Scholar
• Stone M H. Long-term outcome in personality disorders. Br J Psychiatry 1993; 162: 299–313
   PubMed Web of Science ®Google Scholar
• McGlashan T H. The Chestnut Lodge follow-up study. III. Long-term outcome of borderline personalities. Arch Gen Psychiatry 1986; 43: 20–30
   PubMed Web of Science ®Google Scholar
• Zanarini M C, Gunderson J G, Frankenburg F R. Axis I phenomenology of borderline personality disorder. Compr Psychiatry 1989; 30: 149–56
   PubMedGoogle Scholar
• Zanarini M C, Williams A A, Lewis R E, et al. Reported pathological childhood experiences associated with the development of borderline personality disorder. Am J Psychiatry 1997; 154: 1101–6
   PubMed Web of Science ®Google Scholar
• Zanarini M C, Frankenburg F R, Dubo E D, et al. Axis I comorbidity of borderline personality disorder. Am J Psychiatry 1998; 155: 1733–9
   PubMed Web of Science ®Google Scholar
• Zimmerman M, Mattia J I. Axis I diagnostic comorbidity and borderline personality disorder. Compr Psychiatry 1999; 40: 245–52
   PubMed Web of Science ®Google Scholar
• Skodol A E, Oldham J M, Gallaher P E. Axis II comorbidity of substance use disorders among patients referred for treatment of personality disorders. Am J Psychiatry 1999; 156: 733–8
   PubMed Web of Science ®Google Scholar
• Frankenburg F R, Zanarini M C. The association between borderline personality disorder and chronic medical illnesses, poor health-related lifestyle choices, and costly forms of health care utilization. J Clin Psychiatry 2004; 65: 1660–5
   PubMed Web of Science ®Google Scholar
• McEwen BS. Corticosteroids and hippocampal plasticity. Ann N Y Acad Sci 1994; 746: 134–42
   Google Scholar
• Sapolsky R M. Stress and plasticity in the limbic system. Neurochem Res 2003; 28: 1735–42
   PubMed Web of Science ®Google Scholar
• Dunn A J, Berridge C W. Physiological and behavioral responses to corticotrophin-releasing factor administration: is CRF a mediator of anxiety or stress responses?. Brain Res Brain Res Rev 1990; 15: 71–100
   PubMed Web of Science ®Google Scholar
• Bale T L, Contarino A, Smith G W, et al. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet 2000; 24: 410–4
   PubMed Web of Science ®Google Scholar
• Nemeroff C B, Vale W W. The neurobiology of depression: inroads to treatment and new drug discovery. J Clin Psychiatry 2005; 66(suppl 7)5–13
   PubMed Web of Science ®Google Scholar
• Packan D R, Sapolsky R M. Glucocorticoid endangerment of the hippocampus: tissue, steroid and receptor specificity. Neuroendocrinology 1990; 51: 613–8
   PubMed Web of Science ®Google Scholar
• Bremner J D. Does stress damage the brain?. Biol Psychiatry 1999; 45: 797–805
   PubMed Web of Science ®Google Scholar
• Sonino N, Fava G A. Psychosomatic aspects of Cushing's disease. Psychother Psychosom 1998; 67: 140–6
   PubMed Web of Science ®Google Scholar
• Musselman D L, Nemeroff C B. Depression and endocrine disorders: focus on the thyroid and adrenal system. Br J Psych Suppl 1996; 30: 123–8
   Google Scholar
• Herman J P, Ostrander M M, Mueller N K, Figueiredo H. Limbic system mechanisms of stress regulation: hypothalamo-pituitary-adrenocortical axis. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 1201–13
   PubMed Web of Science ®Google Scholar
• Val E, Nasr S J, Filogonio M G, Prasad R B. Letter to the editor. Am J Psychiatry 1983; 140: 6
   Google Scholar
• Ferrari M, Mantero F. Male aging and hormones: the adrenal cortex. J Endocrinol Invest 2005; 28(11)92–5, suppl proceedings
   Google Scholar
• Kirschbaum C, Kudielka B M, Gaab J, Schommer N C, Hellhammer D H. Impact of gender, menstrual cycle phase, and oral contraceptives on the activity of the hypothalamus-pituitary-adrenal axis. Psychosom Med 1999; 61: 154–62
   PubMed Web of Science ®Google Scholar
• Rohleder N, Kirschbaum C. Effects of nutrition on neuro-endocrine stress responses. Curr Opin Clin Nutr Metab Care 2007; 10: 504–10
   PubMed Web of Science ®Google Scholar
• Kokkoris P, Pi-Sunyer F X. Obesity and endocrine disease. Endocrinol Metab Clin North Am 2003; 32: 895–914
   PubMed Web of Science ®Google Scholar
• Buckley T M, Schatzberg A S. On the interactions of the hypothalamic-pituitary-adrenal (HPA) axis and sleep: normal HPA axis activity and circadian rhythm, exemplary sleep disorders. J Clin Endocrinol Metab 2005; 90: 3106–14
   PubMed Web of Science ®Google Scholar
• Rinne T, de Kloet E R, Wouters L, Goekoop J G, DeRijk R H, van den Brink W. Hyperresponsiveness of hypothalamic-pituitary-adrenal axis to combined dexamethasone/corticotropin-releasing hormone challenge in female borderline personality disorder subjects with a history of sustained child abuse. Biol Psychiatry 2002; 52: 1102–12
   PubMed Web of Science ®Google Scholar
• Lange W, Wulff H, Berea C, et al. Dexamethasone suppression test in borderline personality disorder—effects of posttraumatic stress disorder. Psychoendocrinology 2005; 30: 919–23
   Google Scholar
• Simeon D, Knutelska M, Smith L, Baker B R, Hollander E. A preliminary study of cortisol and norepinephrine reactivity to psychosocial stress in borderline personality disorder with high and low dissociation. Psychiatry Res 2007; 149: 177–84
   PubMed Web of Science ®Google Scholar
• Lieb K, Rexhausen J E, Kahl K G, et al. Increased diurnal salivary cortisol in women with borderline personality disorder. J Psychiatr Res 2004; 38: 559–65
   PubMed Web of Science ®Google Scholar
• Carrasco J L, Diaz-Marsa M, Pastrana J I, et al. Hypothalamic-pituitary-adrenal axis response in borderline personality disorder without post-traumatic features. Br J Psychiatry 2007; 190: 357–8
   Google Scholar
• Southwick S M, Axelrod S R, Wang S, et al. Twenty-four-hour urine cortisol in combat veterans with PTSD and comorbid borderline personality disorder. J Nerv Ment Dis 2003; 191: 261–2
   PubMed Web of Science ®Google Scholar
• Stokes P E, Sikes C R. Hypothalamic-pituitary-adrenal axis in psychiatric disorders. Annu Rev Med 1991; 42: 519–31
   PubMed Web of Science ®Google Scholar
• APA Task Force on Laboratory Tests in Psychiatry. The dexamethasone suppression test: an overview of its current status in psychiatry. Am J Psychiatry 1987; 144: 1253–62
   PubMed Web of Science ®Google Scholar
• Gillespie C F, Nemeroff C B. Hypercortisolemia and depression. Psychosom Med 2005; 67(suppl 1)S26–8
   PubMed Web of Science ®Google Scholar
• Keller P A, McCluskey A, Morgan J, O'Connor S M. The role of the HPA axis in psychiatric disorders and CRF antagonists as potential treatments. Arch Pharm (Weinheim) 2006; 339: 346–55
   Web of Science ®Google Scholar
• Carroll B J, Greden J F, Feinberg M, et al. Neuroendocrine evaluation of depression in borderline patients. Psychiatr Clin North Am 1981; 4: 89–99
   PubMed Web of Science ®Google Scholar
• Sternbach H A, Fleming J, Extein I, Pottash A L, Gold M S. The dexamethasone suppression and thyrotropin-releasing hormone tests in depressed borderline patients. Psychoneuroendocrinology 1983; 8: 459–62
   PubMed Web of Science ®Google Scholar
• Steiner M, Martin S, Wallace J E, Goldman S. Distinguishing subtypes within the borderline domain: a combined neuroendocrine approach. Biol Psychiatry 1984; 19: 907–11
   Google Scholar
• Baxter L, Edell W, Gerner R, Fairbanks L, Gwirtsman H. Dexamethasone suppression test and Axis I diagnoses of inpatients with DSM-III borderline personality disorder. J Clin Psychiatry 1984; 45: 150–3
   PubMedGoogle Scholar
• Beeber A R, Kline M D, Pies R W, Manring J M. Jr. Dexamethasone suppression test in hospitalized depressed patients with borderline personality disorder. J Nerv Ment Dis 1984; 172: 301–3
   Google Scholar
• Soloff P H, George A, Nathan R S. The dexamethasone suppression test in patients with borderline personality disorders. Am J Psychiatry 1982; 139: 1621–3
   Google Scholar
• Krishnan K R, Davidson J R, Rayasam K, Shope F. The dexamethasone suppression test in borderline personality disorder. Biol Psychiatry 1984; 19: 1149–53
   Google Scholar
• Lahmeyer H W, Val E, Gaviria M, et al. EEG sleep, lithium transport, dexamethasone suppression, and monoamine oxidase activity in borderline personality disorder. Psychiatry Res 1988; 25: 19–30
   PubMedGoogle Scholar
• Korzekwa M, Steiner M, Links P, Eppel A. The dexamethasone suppression test in borderlines: is it useful?. Can J Psychiatry 1991; 36: 26–8
   Google Scholar
• De l a, Fuente J M, Mendlewicz J. TRH stimulation and dexamethasone suppression in borderline personality disorder. Biol Psychiatry 1996; 40: 412–8
   Google Scholar
• Kontaxakis V, Markianos M, Vaslamatzis G, Markidis M, Kanellos P, Stefanis C. Multiple neuroendocrinological responses in borderline personality disorder patients. Acta Psychiatr Scand 1987; 76: 593–7
   PubMedGoogle Scholar
• McGlashan T H, Grilo C M, Skodol A E, et al. The Collaborative Longitudinal Personality Disorders Study: baseline Axis I/II and II/II diagnostic co-occurrence. Acta Psychiatr Scand 2000; 102: 256–64
   PubMed Web of Science ®Google Scholar
• Herman J L. Trauma and recovery. Basic, New York 1992
   Google Scholar
• Gunderson J G, Sabo A N. The phenomenological and conceptual interface between borderline personality disorder and PTSD. Am J Psychiatry 1993; 150: 19–27
   PubMed Web of Science ®Google Scholar
• Rasmusson A M, Vythilingam M, Morgan C A. The neuroendocrinology of posttraumatic stress disorder: new directions. CNS Spectr 2003; 8: 651–6; 665–7
   PubMed Web of Science ®Google Scholar
• Grossman R, Yehuda R, New A, et al. Dexamethasone suppression test findings in subjects with personality disoders: associations with posttraumatic stress disorder and major depression. Am J Psychiatry 2003; 160: 1291–8
   PubMed Web of Science ®Google Scholar
• Wingenfeld K, Lange W, Wulff H, et al. Stability of the dexamethasone suppression test in borderline personality disorder with and without comorbid PTSD: a one-year follow-up study. J Clin Psychol 2007; 63: 843–50
   Google Scholar
• Wingenfeld K, Hill A, Adam B, Driessen M. Dexamethasone suppression test in borderline personality disorder: impact of PTSD symptoms. Psychiatry Clin Neurosci 2007; 61: 681–3
   PubMedGoogle Scholar
• Heuser I, Yassouridis A, Holsboer F. The combined dexamethsone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res 1994; 28: 341–56
   PubMed Web of Science ®Google Scholar
• Muhtz C, Wester M, Yassouridis A, Wiedemann K, Kellner M. A combined dexamethsone/corticotropin releasing hormone test in patients with chronic PTSD—first preliminary results. Journal of Psychiatr Res 2008; 42: 689–93
   Web of Science ®Google Scholar
• Kirschbaum C, Pirke K M, Hellhammer D H. The Trier Social Stress Test: a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology 1993; 28: 1186–97
   Google Scholar
• Zanarini M C, Frankenburg F R, Hennen J, Reich D B, Silk K R. Prediction of the 10-year course of borderline personality disorder. Am J Psychiatry 2006; 163: 827–32
   PubMed Web of Science ®Google Scholar
• Lahmeyer H W, Reynolds C F, III, Kupfer D J, King R. Biologic markers in borderline personality disorder. J Clin Psychiatry 1989; 50: 217–25
   PubMedGoogle Scholar
• Schmahl C, Bremner J D. Neuroimaging in borderline personality disorder. J Psychiatr Res 2006; 40: 419–27
   PubMed Web of Science ®Google Scholar
• Juengling F D, Schmahl C, Hesslinger B, et al. Positron emission tomography in female patients with borderline personality disorder. J Psychiatr Res 2003; 37: 109–15
   PubMed Web of Science ®Google Scholar
• Herbert J, Goodyer I M, Grossman A B, et al. Do corticosteroids damage the brain?. J Neuroendocrinol 2006; 18: 393–411
   PubMed Web of Science ®Google Scholar
• Fertuck E A, Lenzenweger M F, Clarkin J F, Hoermann S, Stanley B. Executive neurocognition, memory systems, and borderline personality disorder. Clin Psychol Rev 2006; 26: 346–75
   PubMed Web of Science ®Google Scholar
• Seckl J R, Meaney M J. Glucocorticoid programming. Ann N Y Acad Sci 2004; 1032: 63–84
   PubMed Web of Science ®Google Scholar
• Arato M, Banki C M, Bissette G, Nemeroff C B. Elevated CSF CRF in suicide victims. Biol Psychiatry 1989; 25: 355–9
   PubMed Web of Science ®Google Scholar
• Heim C, Nemeroff C B. The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies. Biol Psychiatry 2001; 49: 1023–39
   PubMed Web of Science ®Google Scholar
• Owens M J, Nemeroff C B. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 1991; 43: 425–73
   PubMed Web of Science ®Google Scholar
• Habib K E, Weld K P, Rice K C, et al. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci U S A 2000; 97: 6079–84
   PubMed Web of Science ®Google Scholar
• French J A, Fite J E, Jensen H, et al. Treatment with CRH-1 antagonist antalarmin reduces behavioral and endocrine responses to social stressors in marmosets (Callithrix kuhlii). Am J Primatol 2007; 69: 877–89
   PubMed Web of Science ®Google Scholar
• Zobel A W, Nickel T, Künzel H E, et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 2000; 34: 171–81
   PubMed Web of Science ®Google Scholar
• Suomi S J. Early stress and adult emotional reactivity in rhesus monkeys. Ciba Found Symp 1991; 156: 171–83
   PubMedGoogle Scholar
• Brady L S, Gold P, Herkenham M, Lynn A, Whitfeld H J. The antidepressants fluoxetine, idazoxan, and phenelzine alter corticotrophin releasing hormone, tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res 1992; 572: 117–25
   PubMed Web of Science ®Google Scholar
• Brady L S, Whitfeld H J, Fox R J, Gold P W, Herkenham M. Long-term antidepressant administration alters cortico- trophin-releasing hormone, tyrosine hydroxylase and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications. J Clin Invest 1991; 87: 831–7
   PubMed Web of Science ®Google Scholar
• Veith R C, Lewis N, Langohr J L, et al. Effect of desipramine on cerebrospinal fluid concentrations of corticotrophin-releasing factor in human subjects. Psychiatry Res 1993; 46: 1–8
   PubMed Web of Science ®Google Scholar
• Michelson D, Galliven E, Hill L, Demitrack M, Chrousis G, Gold P. Chronic imipramine is associated with diminished hypothalamic-pituitary-adrenal axis responsivity in healthy humans. J Clin Endrocrinol Metab 1997; 82: 2601–6
   PubMed Web of Science ®Google Scholar
• Nemeroff C B, Heim C M, Thase M E, et al. Differential responses to psychotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci U S A 2003; 100: 14293–6
   PubMed Web of Science ®Google Scholar
• Gillespie C F, Nemeroff C B. Corticotropin-releasing factor and the psychobiology of early-life stress. Curr Dir Psychol Sci 2007; 16: 85–9
   Web of Science ®Google Scholar
• Gunderson J G, Stout R L, Sanislow S A, et al. New episodes and new onsets of major depression in borderline and other personality disorders. J Affect Disord 2008; 111: 40–5
   PubMed Web of Science ®Google Scholar